Elan affiliate Athena files for IPO

2 November 2001

Elan Corp of Ireland's indirect wholly-owned subsidiary AthenaDiagnostics has filed a registration statement with the US Securities and Exchange Commission for an initial public offering of its common stock, par value $0.01 per share.

The proposed offering will involve only the sale of a portion of the existing shares of common stock held in Athena by its sole shareholder, Elan Pharmaceuticals. It is anticipated that the offering will start in early-2002, with UBS Warburg LLC as the lead underwriter.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight